Sputum Color Linked to Bronchiectasis Inflammation Level
Patients with bronchiectasis can track sputum changes as a potential indicator of worsening inflammation and disease severity.
Updated on Oct. 21, 2026 in Asthma
Live Poll
Do you believe simple self-monitoring tools help you better manage your respiratory health?
New data from the phase III ASPEN trial confirms that sputum color serves as a reliable indicator of inflammation severity in patients with bronchiectasis. The findings also suggest that the investigational treatment brensocatib effectively reduces protease activity regardless of a patient's baseline sputum type.
Why it matters
Understanding the link between sputum color and airway inflammation helps patients and clinicians better monitor disease activity and exacerbation risk. This study highlights how daily symptom tracking can provide early warning signs of worsening respiratory health.
A Phase III randomized trial analysis of 326 patients found that higher sputum purulence correlates with increased neutrophil serine protease activity and lower lung function. Researchers observed that brensocatib treatment consistently reduced this protease activity across all sputum categories.
The players
ASPEN trial
A Phase III clinical research study investigating the efficacy of brensocatib in managing bronchiectasis exacerbations.
Chest 2026
An international professional conference hosted by the American College of Chest Physicians to present advances in pulmonary and critical care medicine.
The details
Sputum purulence is a marker for neutrophil activity, which drives inflammation and tissue damage in bronchiectasis. The ASPEN trial utilized the Bronchiectasis Exacerbation and Symptom Tool to track patient-reported sputum color daily. Researchers evaluated whether 10 mg or 25 mg daily doses of brensocatib could inhibit the neutrophil serine proteases—NE, CatG, and PR3—that contribute to airway destruction during exacerbations.
Timeline
Patients experienced at least two pulmonary exacerbations in the 12 months before screening.
The clinical trial treatment period lasted 52 weeks.
Findings were presented at the Chest 2026 conference in October 2026.
Health Landscape
This research follows the pattern established by the ASPEN trial in evaluating targeted anti-inflammatory therapies for chronic lung conditions. It represents a shift toward using patient-reported outcomes to validate the efficacy of emerging treatments like brensocatib in real-world clinical contexts.
If you are managing bronchiectasis, tracking changes in your daily sputum color may offer a simple way to identify when your airway inflammation is increasing. Discussing these daily observations with your pulmonologist can help you better tailor your care plan and monitor for potential exacerbations.
The takeaway
Sputum color is a clinically relevant indicator of inflammation and disease severity in patients with bronchiectasis. Patients should keep a daily diary of respiratory symptoms and report shifts toward purulent sputum to their physician immediately.
Further reading
Learn more about the latest research and symptom management tools in our Asthma section.
Source note: This article includes information reported by Respiratory Therapy.
Live Poll
Do you believe simple self-monitoring tools help you better manage your respiratory health?
